Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:EYEG OTCMKTS:SEOVF NASDAQ:SXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.53-24.8%$0.78$0.48▼$2.48$15.67M1.051.08 million shs2.56 million shsEYEGAB Corporate Bond ETF$34.97-0.1%$35.29$34.59▼$36.63$27.98M0.18227 shs3,342 shsSEOVFSernova Biotherapeutics$0.13+10.5%$0.12$0.09▼$0.16$44.45M0.8631,644 shs31,000 shsSXTCChina SXT Pharmaceuticals$1.57-0.6%$1.84$1.25▼$1,046.99$1.52M1.9621,593 shs8,330 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-24.76%-17.48%-38.60%-28.93%-37.88%EYEGAB Corporate Bond ETF-0.11%-0.96%-1.96%-3.15%+0.06%SEOVFSernova Biotherapeutics+10.45%+11.30%-6.88%+25.00%-13.33%SXTCChina SXT Pharmaceuticals-0.63%-4.85%-21.89%-37.45%-99.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.53-24.8%$0.78$0.48▼$2.48$15.67M1.051.08 million shs2.56 million shsEYEGAB Corporate Bond ETF$34.97-0.1%$35.29$34.59▼$36.63$27.98M0.18227 shs3,342 shsSEOVFSernova Biotherapeutics$0.13+10.5%$0.12$0.09▼$0.16$44.45M0.8631,644 shs31,000 shsSXTCChina SXT Pharmaceuticals$1.57-0.6%$1.84$1.25▼$1,046.99$1.52M1.9621,593 shs8,330 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-24.76%-17.48%-38.60%-28.93%-37.88%EYEGAB Corporate Bond ETF-0.11%-0.96%-1.96%-3.15%+0.06%SEOVFSernova Biotherapeutics+10.45%+11.30%-6.88%+25.00%-13.33%SXTCChina SXT Pharmaceuticals-0.63%-4.85%-21.89%-37.45%-99.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.20Hold$5.00848.77% UpsideEYEGAB Corporate Bond ETF 0.00N/AN/AN/ASEOVFSernova Biotherapeutics 0.00N/AN/AN/ASXTCChina SXT Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SXTC, SEOVF, EYEG, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CTXRCitius Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.005/1/2026SXTCChina SXT Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)3/27/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/11/2026CTXRCitius Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$4.29 per shareN/AEYEGAB Corporate Bond ETF$12.06K2,319.99N/AN/A$1.26 per share27.75SEOVFSernova BiotherapeuticsN/AN/AN/AN/A($0.05) per shareN/ASXTCChina SXT Pharmaceuticals$1.74M0.87N/AN/A$3,187.45 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$37.43M-$2.45N/AN/AN/AN/A-59.09%-35.33%N/AEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/ASEOVFSernova Biotherapeutics-$11.24M-$0.04N/AN/AN/AN/AN/A-761.41%6/11/2026 (Estimated)SXTCChina SXT Pharmaceuticals-$3.30MN/AN/AN/AN/AN/AN/AN/AN/ALatest SXTC, SEOVF, EYEG, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026N/ASEOVFSernova Biotherapeutics-$0.0074N/AN/AN/AN/AN/A5/15/2026Q2 2026CTXRCitius Pharmaceuticals$0.3885-$0.95-$1.3385-$0.95$18.79 million$1.67 million3/19/2026Q1 2026SEOVFSernova Biotherapeutics-$0.0073-$0.01-$0.0027-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETF$1.744.98%N/AN/A N/ASEOVFSernova BiotherapeuticsN/AN/AN/AN/AN/ASXTCChina SXT PharmaceuticalsN/AN/AN/AN/AN/ALatest SXTC, SEOVF, EYEG, and CTXR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026EYEGAB Corporate Bond ETFmonthly$0.14044.78%5/1/20265/1/20265/6/20263/31/2026EYEGAB Corporate Bond ETFmonthly$0.14334.89%4/1/20264/1/20264/7/20262/27/2026EYEGAB Corporate Bond ETFmonthly$0.13934.68%3/2/20263/2/20263/5/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.990.40EYEGAB Corporate Bond ETF0.013.073.07SEOVFSernova BiotherapeuticsN/A0.030.03SXTCChina SXT PharmaceuticalsN/A4.374.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%EYEGAB Corporate Bond ETF64.16%SEOVFSernova BiotherapeuticsN/ASXTCChina SXT Pharmaceuticals5.02%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals4.99%EYEGAB Corporate Bond ETF58.20%SEOVFSernova BiotherapeuticsN/ASXTCChina SXT Pharmaceuticals3.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2022.38 million21.26 millionOptionableEYEGAB Corporate Bond ETF14800,0005.28 millionNot OptionableSEOVFSernova BiotherapeuticsN/A377.64 millionN/ANot OptionableSXTCChina SXT Pharmaceuticals90960,000925,000Not OptionableSXTC, SEOVF, EYEG, and CTXR HeadlinesRecent News About These CompaniesChina SXT Pharmaceuticals Raises $3.5 Million in Offshore Private PlacementMay 11, 2026 | theglobeandmail.comChina Sxt Pharmaceuticals, Inc. Class AApril 7, 2026 | edition.cnn.comChina SXT Pharmaceuticals, Inc. Announces Share Re-classificationMarch 23, 2026 | globenewswire.comThis nano-cap pharma stock crashed 30% today – what triggered the sell-off?January 30, 2026 | msn.comChina SXT Pharmaceuticals, Inc. Announces Share ConsolidationJanuary 30, 2026 | globenewswire.comCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAINJanuary 15, 2026 | finance.yahoo.comUnivest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)January 13, 2026 | globenewswire.comWhy China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 8.81%January 11, 2026 | aaii.comAChina SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct OfferingJanuary 9, 2026 | globenewswire.comCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND ...January 8, 2026 | markets.businessinsider.comWhy China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Up 6.88%January 3, 2026 | aaii.comAChina SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)August 2, 2025 | finance.yahoo.comChina SXT Pharmaceuticals Inc. (SXTC) Stock Price Today - WSJJuly 30, 2025 | wsj.comChina SXT Pharmaceuticals, Inc. (SXTC) - Yahoo FinanceJuly 4, 2025 | sg.finance.yahoo.comChina SXT Pharmaceuticals Inc News (SXTC) - Investing.comJune 25, 2025 | investing.comChina SXT Pharmaceuticals Issues 90 Million Shares Following Warrant ExerciseJune 16, 2025 | tipranks.comChina SXT Pharmaceuticals Inc Ordinary SharesApril 23, 2025 | morningstar.comMChina SXT Pharmaceuticals Reports Financial Results Amid Regulatory ChallengesMarch 28, 2025 | tipranks.comChina SXT Pharmaceuticals Optimizes Capital Structure with Warrant ExchangeMarch 19, 2025 | tipranks.comChina SXT Pharmaceuticals regains compliance with NasdaqMarch 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSXTC, SEOVF, EYEG, and CTXR Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.53 -0.17 (-24.76%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$0.53 +0.01 (+1.33%) As of 05:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.AB Corporate Bond ETF NASDAQ:EYEG$34.97 -0.02 (-0.05%) Closing price 05/18/2026 03:37 PM EasternExtended Trading$37.87 +2.90 (+8.29%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Sernova Biotherapeutics OTCMKTS:SEOVF$0.13 +0.01 (+10.45%) As of 05/18/2026 02:35 PM EasternSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.China SXT Pharmaceuticals NASDAQ:SXTC$1.57 -0.01 (-0.63%) Closing price 05/18/2026 03:51 PM EasternExtended Trading$1.57 0.00 (0.00%) As of 05:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
